Treatment of idiopathic pulmonary fibrosis

Craig E. Daniels, Jay H Ryu

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive lung disease in most cases, and effective treatment is still lacking. This review examines the current status of treatment options and complexities in the management of patients with IPF. Although optimal therapy for IPF has not been identified, ongoing research efforts warrant reason for optimism. Current management of IPF includes not only judicious use of available pharmacological agents tailored to individual circumstances but also patient education through realistic assessment of prognosis, discussion of pros and cons of pharmacotherapy, early consideration of lung transplantation when applicable, treatment of complications, supportive care, and encouragement to participate in clinical trials.

Original languageEnglish (US)
Pages (from-to)668-676
Number of pages9
JournalSeminars in Respiratory and Critical Care Medicine
Volume27
Issue number6
DOIs
StatePublished - Dec 2006

    Fingerprint

Keywords

  • Bosentan
  • Idiopathic pulmonary fibrosis
  • N-acetylcysteine
  • Pirfenidone
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Critical Care

Cite this